QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has entered into agreement with Florida-based Applied Science and Performance Institute (“ASPI”). The agreement outlines plans to conduct a randomized, double-blind, placebo-controlled crossover study designed to assess the safety and efficacy of FSD Pharma’s unbuzzd(TM). The study will be conducted with healthy volunteers in an induced state of alcohol intoxication. A unique dietary supplement with natural ingredients, vitamins and Generally Recognized as Safe (“GRAS”) ingredients, unbuzzd exhibits potential…